Announcements
PATHFINDER Results Support Feasibility of Multi-Cancer Early Detection (MCED) Testing in Clinical Practice of Eligible Patients Accuracy of Cancer Signal Origin Prediction of MCED Testing Enabled Targeted Diagnostic Evaluations; Majority of Participants Achieved Diagnostic Resolution in Less Than Three Months Adding MCED Testing to Standard of Care Screening More Than Doubled the Number of New…
Read More
Excerpt from the Press Release: SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor.…
Read More
BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetes Excerpt from the Press Release: REDWOOD CITY, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to…
Read More
Collaboration with OICR and capital from FACIT contributing to a growing hub of medical imaging research in Thunder Bay. Excerpt from the Press Release: When Sasha Bubon arrived in Thunder Bay in January 2010 to begin his master’s studies in physics at Lakehead University, he was starting a whole new chapter personally and scientifically. …
Read More
Collaboration with CardioNXT provides navigation and mapping system integration with Pulse Biosciences’ nsPFA circumferential catheter to support first-in-human treatments Excerpt from the Press Release: HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation,…
Read More
Christopher Kata and the TrialStat team are exhibiting at this years Clinical Outsourcing Group West Coast meeting on November 7th through the 8th in Burlingame, California. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #34 at your convenience! We’re looking forward…
Read More
Excerpt from the Press Release: SAN FRANCISCO, Calif. – October 2, 2023 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced eight data presentations (from an Attralus sponsored trial and from four investigator-initiated trials) related to the use of 124I-evuzamitide (AT-01), the company’s…
Read More
I.V.-Delivered Vector Core to Akamis Bio T-SIGn® Therapeutics; Phase 1 Study Data to be Presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting Excerpt from the Press Release: CAMBRIDGE, Mass. & OXFORD, England–(BUSINESS WIRE)–Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene (T-SIGn®) therapy platform to deliver novel immunotherapeutic proteins,…
Read More Excerpt from the Press Release: SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / October 3, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from different solid tumors or hematological malignancies with significant unmet medical needs, today…
Read More
— Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors — Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for control treatment Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) — ALX…
Read More